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Summary
There is an urgent need to develop novel approaches to vaccination against the emerging, highly
pathogenic avian influenza viruses. Here, we engineered influenza viral-like particles (Flu-VLPs)
derived from retroviral core particles that mimic the properties of the viral surface of two highly
pathogenic influenza viruses of either H7N1 or H5N1 antigenic subtype. We demonstrate that,
upon recovery of viral RNAs from a field strain, one can easily generate expression vectors that
encode the HA, NA and M2 surface proteins of either virus and prepare high-titre Flu-VLPs. We
characterise these Flu-VLPs incorporating the HA, NA and M2 proteins and we show that they
induce high-titre neutralising antibodies in mice.
Influenza virus infects thousands of people each year,
causing epidemics with severe mortality [1]. Moreover,
there is an increasing concern about a potential influenza
pandemic, as highly virulent avian influenza strains are
spreading from South-East Asia, with a high risk to cross
species-specific barriers [2]. With such a menace, we
should be well prepared to prevent excessive mortality,
should a virulent pandemic occur.
Vaccination, so far, has been the best manner to protect
individuals from influenza infection. Influenza vaccines
have been used for ca. 50 years [3]. Current influenza vac-
cines are mostly inactivated formulations relying on the
antigenic activity of the surface glycoproteins of influenza
virus: a hemagglutinin (HA) and a neuraminidase (NA)
[4]. A major problem, when preparing an influenza vac-
cine, is the lack of cross-immunity generated against dif-
ferent influenza virus subtypes. This is due to the high
mutagenic capacity of influenza virus to generate forms
that can escape the immune system. Antigenic shifts and
antigenic drifts are evolutionary mechanisms that lead to
serologically different influenza virus subtypes or strains
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against which a vaccine is not efficient [5]. Thus, new vac-
cines need to be prepared during each seasonal influenza
epidemic and, importantly, there is no vaccine against the
novel, emerging highly pathogenic viruses. Influenza vac-
cines are generally produced from virus grown in embry-
onated chicken eggs. This implies that manufacturing a
vaccine preparation, from the appearance of a new sub-
type of influenza virus until the readiness of the vaccine,
takes several months [6]. Moreover, one needs to modify
the HA of highly virulent influenza strains in order to be
able to produce vaccines without killing the embryos.
Recently, reverse genetic methods have been used to pro-
duce vaccines in cell culture [6,7]. Finally, in the event of
a pandemic, the vaccine production has to be massive,
quick and safe.
Altogether, there is a strong need for developing novel
immunogenic formulations that can rapidly be prepared
as vaccines against the emerging highly pathogenic avian
influenza virus. As a step along this road, here we describe
a novel influenza virus immunogen using engineered
viral-like particles (Flu-VLPs) that mimic the properties of
the viral surface of two highly pathogenic influenza
viruses of H7N1 and H5N1 subtypes.
We used the surface proteins HA, NA and M2 of two
highly pathogenic avian influenza viruses: A/Chicken/
FPV/Rostock/1934 (H7N1) [8] and A/Thailand/KAN-1/
04 (H5N1) [9,10] to generate Flu-VLPs (H7-VLPs and H5-
VLPs, respectively). The influenza hemagglutinin is
responsible for virion attachment to the target cells
through recognition and binding to terminal sialic acid
groups on membrane-bound proteins of the host cell
(reviewed in [11]). The neuraminidase destroys non-func-
tional receptors to which hemagglutinin can bind and
thus facilitates virus access to target cells at the early stages
of infection and promotes egress of progeny viral particles
from infected cells late in infection [12,13]. M2 is a small
transmembrane protein with an ion channel activity
which regulates the pH inside the virion during viral entry
into cell and protects newly synthesized acid-labile H5
and H7 hemagglutinins during their transport through
low pH cellular compartments (reviewed in [14,15]).
Cloning of expression vectors for HA, NA and M2 from
H7N1 virus has been described elsewhere [8,16-19]. The
human virus isolate of H5N1, A/Thailand/KAN-1/04
(H5N1) [9], was kindly provided by Pilaipan Putha-
vathana at Mahidol University, Bangkok, Thailand. We
made one passage of the original seed virus in MDCK cells
and isolated viral RNA using the High Pure RNA isolation
kit (Roche Molecular Biochemicals, Mannheim, Ger-
many). HA, NA and M2 coding sequences were then
amplified from total viral RNA using Superscript Reverse
transcriptase and specific primers (sequences are available
upon request). PCR products were introduced into a CMV
promoter-driven expression plasmid in a manner identi-
cal to that used for H7N1 [18].
Flu-VLPs were assembled on replication-defective core
particles derived from murine leukaemia virus (MLV). For
immunisation purposes, they consisted of empty "core"
particles generated by the sole expression of MLV Gag pro-
teins [20], whereas for infectious assays, they comprised
MLV GagPol proteins and a recombinant genome encod-
ing the green fluorescent protein (GFP) [16,19]. Transduc-
tion of this marker gene in 'infected' target cells and
expression of GFP in transduced cells is indeed an accurate
reflection of the infection steps mediated by the surface
glycoproteins of retrovirus-derived VLPs [17,21,22] and,
hence, is a convenient way to study cell entry and neutral-
isation of highly pathogenic viruses in category 2 labora-
tories [23-25]. We produced Flu-VLPs harbouring at their
surface HA, HA and either NA or M2, or all three proteins
derived from the H7N1 or H5N1 viruses, by transient
expression in 293T cells of surface (HA, NA, M2) and
internal (Gag, GFP marker genome) viral components.
Expression of the different viral proteins in producer cells
and their incorporation on sucrose cushion-purified viral
particles was characterized by Western blot using specific
primary antibodies (Fig. 1A). All proteins were readily
expressed in producer cells (not shown). The hemaggluti-
nin, detected as uncleaved HA0 precursor and HA1/HA2
cleaved mature forms, was incorporated on the surface of
the viral particles at high levels for both H7-VLPs and H5-
VLPs, when expressed together with NA (Fig. 1A). The
neuraminidase and M2 protein were also detected on
purified viral particles (Fig. 1A), yet at low levels as com-
pared to their expression in producer cells (data not
shown).
The expression of M2 during Flu-VLP production did not
influence the incorporation of HA or NA onto the viral
particles (Fig. 1A). In contrast, only small amounts of HA
proteins were detected on particles when NA was not co-
expressed in producer cells, correlating with low quanti-
ties of MLV Gag-derived capsid (CA) proteins (Fig. 1A).
This was most likely due to a less effective release of VLPs
into the cell supernatant in the absence of NA. Indeed
treatment of these latter cells with purified neuraminidase
from Vibrio cholerae induced efficient release of the viral
particles (data not shown). This confirmed the essential
role of NA to promote the release virus particles from the
cell surface by removing sialic acid receptors from pro-
ducer cells [12,26].
To estimate the concentration of Flu-VLPs, we determined
their 'transduction titres' by adding serial dilutions of viral
particle preparations harbouring a GFP marker gene to
TE671 human rhabdomyosarcoma cells. The medium
was then replaced with normal culture medium and the
Virology Journal 2006, 3:70 http://www.virologyj.com/content/3/1/70
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Biochemical and functional analysis of Flu-VLPsF gur  1
Biochemical and functional analysis of Flu-VLPs. A. Incorporation of HA, NA and M2 proteins from H7N1 (A/Chicken/
FPV/Rostock/1934) or H5N1 (A/Thailand/KAN-1/04) influenza viruses on MLV retroviral core particles, as indicated. Purified 
VLPs were loaded on SDS-PAGE and incorporation levels of the different proteins were determined by Western Blot analysis 
using polyclonal sera against H7N1-HA, H5N3-HA, H7N1-NA and M2 proteins. HA0: HA precursor protein, HA1: HA surface 
subunit; HA2: HA transmembrane subunit; NA: neuraminidase; CA: MLV capsid protein. The difference in the molecular weight 
of H5 vs. H7 HA2, of ca. 3 kDa, was due to the presence of an additional glycan for H7 HA2. B. Infectious titres obtained with 
Flu-VLPs incorporating surface proteins from H7N1 or H5N1 influenza viruses or with VSV-VLPs incorporating the VSV-G of 
vesicular stomatitis virus (VSV), as indicated. VLP-containing supernatants were used to infect 105 TE671 target cells plated in 
12-well for 6 hr at 37°C. The transduction efficiency of GFP, determined as the percentage of GFP-positive cells, was measured 
by fluorescence-activated cell sorter (FACS) analysis 72 hr after infection, as previously described [22]. The transduction titres, 
provided as GFP-transducing units (t.u.)/ml, were calculated by using the formula: Titre = %inf × (105/100) × d, where "d" is the 
dilution factor of the viral supernatant and "%inf" is the percentage of GFP-positive cells as determined by FACS analysis using 
dilutions of the viral supernatant that transduced between 0.1% and 5% of GFP-positive cells. Due to the use of a FACS 
method to monitor transduced cells, the determination of GFP-positive cell below 0.1%, i.e., corresponding to transduction 
titres below 103 t.u./ml in our experimental conditions, could not be accurately be determined. The background levels of trans-
duction were therefore fixed at 103 t.u./ml in all experiments.
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transduction titre was deduced 72 hr later from the per-
centage of GFP-positive cells measured by fluorescence-
activated cell sorter (FACS) analysis, as previously
described [22].
In accordance with biochemical data (Fig. 1A), Flu-VLPs
produced in the absence of NA displayed relatively low
transduction titres, below 105 t.u./ml (Fig. 1B). Consistent
with its effect on HA incorporation (Fig. 1A), the presence
of NA increased the infectivity by about 100 fold for H7-
VLPs and 1,000 fold for H5-VLPs, raising transduction
titres higher than those obtained with VLPs harbouring
VSV-G (VSV-VLPs), one of the most efficient viral surface
glycoprotein in such assays [17]. Of note, the infectivity of
the Flu-VLPs was specifically and completely abolished by
immune sera from animals inoculated with wild type
influenza virus (Fig. 2A).
Interestingly, the transduction titres obtained with H7-
VLPs were about 50-fold lower than those obtained with
H5-VLPs (Fig. 1B). Furthermore, incorporation of M2
onto the Flu-VLPs increased the infectivity of H7-VLPs by
about 10 times (Fig. 1B), as reported previously [27], but
not that of H5-VLPs, as similar H5 HA incorporation lev-
els were reached irrespective of whether or not M2 was
expressed (Fig. 1A). This suggested that H7 HA, but not
H5 HA, was sensitive to M2 functions. Consistent with its
capacity to regulate the internal pH of endosomal com-
partments, the role of M2 during Flu-VLP production is
probably to prevent acidification and premature activa-
tion of HA protein, an event for which H7N1 virus HA is
apparently more sensitive than HA of H5N1 virus strain
used in this study.
Altogether, these results indicated that HA, NA and M2
incorporated onto the surface of VLPs are functional as
they efficiently mediate cell entry.
We then investigated whether Flu-VLPs harbouring all
three viral proteins can induce specific immune responses
and neutralising antibodies in mice. For these studies, H7-
VLPs or H5-VLPs were concentrated and purified by ultra-
centrifugation [19] before injection in BalbC mice. Con-
trol VLPs, incorporating the VSV-G glycoprotein [17,18],
were also prepared and injected to mice in parallel. As an
attempt to induce cross-neutralising antibodies against
different influenza strains, we generated H7-VLPs or H5-
VLPs treated with a citrate buffer at pH5.3 for 10 minutes.
Indeed, at low pH, HA undergoes irreversible conforma-
tional changes that are required to induce membrane
fusion [28]. Such conformational changes alter the struc-
ture and antigenicity of HA [29,30] and may result in
exposure of conserved epitopes, hidden in the native HA
conformation, that could induce cross-neutralising anti-
bodies that are not raised otherwise, particularly in con-
served regions of HA2 [31]. Conformational changes were
verified by demonstration of a complete loss of infectivity
by low pH-treated particles (data not shown) [28].
About 108 particles of H7-VLPs or H5-VLPs, treated or
non-treated at low pH, as well as VSV-VLPs particles were
repeatedly injected intraperitoneally in 5 week-old female
BalbC mice at 2 weeks intervals. The sera were harvested 2
weeks after each injections (harvests S1, S2, S3 and S4)
and were decomplemented by heat inactivation at 56°C
for 1 hr. We next determined the neutralising activity of
the sera using the Flu-VLPs or the VSV-VLPs harbouring a
GFP marker gene. The results of a typical experiment
shown in Fig. 2A, are displayed as the % of neutralisation
of the S2 sera compared to the S0 pre-immune sera, i.e.,
sera harvested before the first inoculation for each mouse,
for a 1/100 dilution of these sera. Sera from mice injected
with H7-VLPs neutralised specifically H7-VLPs, but nei-
ther the H5-VLPs nor the VSV-VLPs and vice-versa. Sera
from mice injected with native Flu-VLPs neutralised more
efficiently the homologous Flu-VLPs than sera from mice
injected with acid pH-denatured Flu-VLPs; yet no cross-
neutralisation was observed for the latter sera. Consist-
ently, as tested on immunoblots of H7-VLPs vs. H5-VLPs,
no cross-reactivity of H7- and H5-VLP sera could be
observed for HA. Antibodies against M2 that detected M2
from either influenza virus strain were raised in some
immunised mice (Fig. 2B), in agreement with the strong
sequence homology between H7 M2 and H5 M2. No
cross-reacting NA antibodies could be detected (Fig. 2B),
perhaps owing to the relatively inefficient incorporation
of this glycoprotein on the Flu-VLPs. Only few other non-
specific protein bands were observed (Fig. 2B), suggesting
that the antibody response against Flu-VLPs was specific.
To investigate how the neutralising titres increased after
repeated immunisations, we determined the titration
curves for each serum harvest. The results are shown in
Fig. 2C as the mean neutralisation values from sera of the
different groups of mice. The neutralisation curves were
similar for both H7 and H5 sera. We found that S1 sera,
harvested 2 weeks after the first injection, had significant
neutralising activity, with 50% neutralising activity-
reached at the 1/500 serum dilution and with an ID90 at
the 1/100 dilution. The S2, S3 and S4 sera had much
higher neutralising activities, even at high dilutions, with
ID95 obtained at the 1/2,500 dilution for the S3 and/or S4
sera.
Altogether these results indicated that retroviral-derived
VLPs incorporating HA, NA and M2 influenza proteins are
able to induce antibody production in mice. Moreover,
the immune response induced by these particles is rapid
and robust, achieving efficient neutralisation only two
weeks after the first injection. The produced antibodies are
specific, as no cross-reaction between different influenza
Virology Journal 2006, 3:70 http://www.virologyj.com/content/3/1/70
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Immunogenicity of Flu-VLPsFigure 2
Immunogenicity of Flu-VLPs. A. Neutralising activity of S2 sera from mice immunised with Flu-VLPs incorporating the HA, 
NA and M2 proteins from H7N1 (lanes 1–8) or H5N1 (lanes 13–20) influenza viruses (H7-VLP and H5-VLP, respectively), or 
with VSV-VLPs harbouring the VSV-G glycoprotein (lanes 9–12). Some Flu-VLPs were treated at acidic pH5.3 (H7-VLP (A) and 
H5-VLP (A)) to induce irreversible conformational changes in the HA protein before injection (lanes 5–8 and lanes 13–16 for 
H7-VLPs and H5-VLPs, respectively). Sera from each mouse were incubated at 37°C for 40 min with H7-VLPs, H5-VLPs or 
VSV-VLPs harbouring a GFP marker gene, as indicated, and then used to infect TE671 target cells. The transduction titres 
determined in the presence of diluted mouse sera were calculated as described in Fig. 1. The results are expressed as the mean 
percentages (mean ± SD; n = 5) of neutralisation of the transduction titres determined with the immune sera relative to titres 
determine with S0 pre-immune sera. Sera or antibodies raised against FPV (fowl plague virus; H7N1 influenza virus) and VSV 
were used as controls in the neutralisation assays (anti-FPV and anti-VSV, respectively). B. Determination of the specificity of 
antibodies raised in S2 sera from mice immunised with Flu-VLPs by Western blot analysis. H7-VLPs (left) and H5-VLPs (right) 
were loaded onto SDS-PAGE and transferred to membrane after electrophoresis. Lanes of these membranes were individual-
ised and separately incubated with S2 sera from immunised mice (see above) at a 1/500 serum dilution. S0: pre-immune serum; 
S. HA; control polyclonal rabbit serum raised H7N1 HA; S. M2; control serum raised against H7 M2; HA0: HA precursor pro-
tein; HA1: HA surface subunit; HA2: HA transmembrane subunit; NA: neuraminidase; M2: M2 matrix protein. C. The neutralis-
ing curves of sera from mice immunised with H7-VLPs and H5-VLPs, harvested two weeks after each injection (S1, S2, S3 and 
S4), were determined for different serum dilutions (1/20, 1/100, 1/500 and 1/2,500). The results are expressed as the mean 
percentages (mean ± SD; n = 5) of neutralisation of the transduction titres determined with the immune sera relative to titres 
determine with S0 pre-immune sera.
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strains was observed. Such engineered Flu-VLPs, which
can be prepared very rapidly as soon as influenza virus
RNAs are isolated, could therefore provide a useful
method to obtain in a timely manner a set of efficient
immunological reagents such as sera, antibodies and
influenza virus-like particles to study neutralisation in low
containment laboratories.
Furthermore, we propose that Flu-VLPs that incorporate
functional influenza virus surface proteins on defective
retroviral core particles could provide a useful immuno-
genic formulation applicable as a vaccine. Such Flu-VLP
can indeed be grown to high titres in mammalian or
insect cell cultures to prepare vaccines in vitro [32], or,
alternatively, could be secreted in vivo upon inoculation
with plasmids [20] or viral vectors [33-35].
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